Gilead Seeks Diversification Into Immuno-oncology Space With $11.9 Billion Kite Buy
August 28, 2017 at 08:59 AM EDT
In a major push into the immuno-oncology space, Gilead Sciences, Inc. (NASDAQ: GILD), which is primarily into antiviral drug ...
